QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
OTCMKTS:KHTRF

Knight Therapeutics - KHTRF Stock Forecast, Price & News

$3.90
0.00 (0.00%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.90
$3.90
50-Day Range
$3.80
$4.06
52-Week Range
$3.79
$4.77
Volume
N/A
Average Volume
2,445 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.55
KHTRF stock logo

About Knight Therapeutics (OTCMKTS:KHTRF) Stock

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its products include ILUVIEN, Nerlynx, Probuphine, Movantik, and Neuragen. The company was founded by Jonathan R. Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KHTRF Stock News Headlines

Berkadia Forges Alliance With Knight Frank
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Knight Therapeutics Closes US$38.5 million Loan with IFC
Knight to Present at Stifel Healthcare Conference
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Knight Therapeutics reports Q4 results
Knight Therapeutics Inc (KHTRF)
Is Knight Therapeutics (TSE:GUD) Using Too Much Debt?
Knight Therapeutics Reports Third Quarter 2021
What Wall Street expects from Knight Therapeutics's earnings
Knight Therapeutics Reports Second Quarter 2021
See More Headlines
Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KHTRF Company Calendar

Today
2/07/2023
Next Earnings (Estimated)
3/22/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:KHTRF
CIK
N/A
Fax
N/A
Employees
660
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.55
High Stock Price Forecast
$7.50
Low Stock Price Forecast
$5.40
Forecasted Upside/Downside
+67.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Samira Sakhia
    President, Chief Executive Officer & Director
  • Utchanah Arvind
    Chief Financial Officer
  • Monica Percario
    Vice President-Global Scientific Affairs
  • Daniela Marino Marino
    Vice President-Legal and Compliance
  • Amal Khouri
    Chief Business Officer













KHTRF Stock - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KHTRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KHTRF, but not buy additional shares or sell existing shares.
View KHTRF analyst ratings
or view top-rated stocks.

What is Knight Therapeutics' stock price forecast for 2023?

1 brokers have issued 12-month price objectives for Knight Therapeutics' shares. Their KHTRF share price forecasts range from $5.40 to $7.50. On average, they expect the company's stock price to reach $6.55 in the next year. This suggests a possible upside of 67.9% from the stock's current price.
View analysts price targets for KHTRF
or view top-rated stocks among Wall Street analysts.

How have KHTRF shares performed in 2023?

Knight Therapeutics' stock was trading at $3.80 at the beginning of the year. Since then, KHTRF shares have increased by 2.6% and is now trading at $3.90.
View the best growth stocks for 2023 here
.

Are investors shorting Knight Therapeutics?

Knight Therapeutics saw a decline in short interest in January. As of January 15th, there was short interest totaling 451,300 shares, a decline of 12.5% from the December 31st total of 515,700 shares. Based on an average trading volume of 2,800 shares, the days-to-cover ratio is presently 161.2 days.
View Knight Therapeutics' Short Interest
.

When is Knight Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our KHTRF earnings forecast
.

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the OTCMKTS under the ticker symbol "KHTRF."

How do I buy shares of Knight Therapeutics?

Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Knight Therapeutics' stock price today?

One share of KHTRF stock can currently be purchased for approximately $3.90.

How many employees does Knight Therapeutics have?

The company employs 660 workers across the globe.

How can I contact Knight Therapeutics?

Knight Therapeutics' mailing address is 3400 de Maisonneuve West, Montréal, QC H3Z. The official website for the company is www.gud-knight.com. The company can be reached via phone at (514) 484-4483.

This page (OTCMKTS:KHTRF) was last updated on 2/7/2023 by MarketBeat.com Staff